← Leaderboards
Elizabeth B. Claus
Yale University
$21,096,464
Attributed
$22,224,249
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,153,420 · 9
By mechanism
U2C$21,858,342 · 4
R01$11,295,078 · 5
Top collaborators
- Bethany Matthews Kwan8 shared
- Roel Gw Verhaak8 shared
Most similar at Yale University
Same institution · by research overlap
- Michael Stuart Leapman$3,095,744
- Michaela Ann Dinan$4,428,713
- Katharine Taylor Ellis$68,480
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisBrain NeoplasmsGeneticTumorResourcesMolecular EvolutionInnovationOperative Surgical ProceduresGenomicsFemaleClinical TrialsEvolutionInternationalMedical RecordsMovementCommunitiesExcisionData CollectionCommunicationCloud BasedEducationEpidemiologyAuthorization DocumentationGlioma
Grant awards (37)
OPTimIzing engageMent in discovery of molecular evolution of low grade glioma (OPTIMUM)$1,999,257
U2C · FY2025 · CA · contact PI
Participant Engagement Unit$942,001
U2C · FY2025 · CA · contact PI
Genome Characterization Unit$793,006
U2C · FY2025 · CA · contact PI
Administrative Core$264,250
U2C · FY2025 · CA · contact PI
OPTimIzing engageMent in discovery of molecular evolution of low grade glioma (OPTIMUM)$771,769
U2C · FY2024 · CA · contact PI
Genome Characterization Unit$425,869
U2C · FY2024 · CA · contact PI
Participant Engagement Unit$306,007
U2C · FY2024 · CA · contact PI
Administrative Core$39,893
U2C · FY2024 · CA · contact PI
OPTimIzing engageMent in discovery of molecular evolution of low grade glioma (OPTIMUM)$1,447,257
U2C · FY2023 · CA · contact PI
Participant Engagement Unit$825,525
U2C · FY2023 · CA · contact PI
Genome Characterization Unit$472,803
U2C · FY2023 · CA · contact PI
Administrative Core$148,929
U2C · FY2023 · CA · contact PI
OPTimIzing engageMent in discovery of molecular evolution of low grade glioma (OPTIMUM)$3,587,938
U2C · FY2022 · CA · contact PI
Participant Engagement Unit$3,269,277
U2C · FY2022 · CA · contact PI
Administrative Core$318,661
U2C · FY2022 · CA · contact PI
OPTimIzing engageMent in discovery of molecular evolution of low grade glioma (OPTIMUM)$3,122,950
U2C · FY2021 · CA · contact PI
Participant Engagement Unit$2,999,293
U2C · FY2021 · CA · contact PI
Administrative Core$123,657
U2C · FY2021 · CA · contact PI
The Meningioma Consortium: Genome-Wide Association Study$597,958
R01 · FY2013 · CA · contact PI
The Meningioma Consortium: Genome-Wide Association Study$259,309
R01 · FY2012 · CA · contact PI
The Meningioma Consortium: Genome-Wide Association Study$532,692
R01 · FY2011 · CA · contact PI
The Meningioma Consortium: Genome-Wide Association Study$2,285,062
R01 · FY2010 · CA · contact PI
Meningioma: Risk Factors and Quality of Life$631,661
R01 · FY2010 · CA · contact PI
Meningioma: Risk Factors and Quality of Life$193,333
R01 · FY2010 · CA · contact PI
Meningioma: Risk Factors and Quality of Life$707,824
R01 · FY2009 · CA · contact PI
Meningioma: Risk Factors and Quality of Life$690,871
R01 · FY2008 · CA · contact PI
Meningioma: Risk Factors and Quality of Life$688,500
R01 · FY2007 · CA · contact PI
Breast Carcinoma In-Situ: Mammographic Risk Factors$295,329
R01 · FY2007 · CA · contact PI
Meningioma: Risk Factors and Quality of Life$535,709
R01 · FY2006 · CA · contact PI
Breast Carcinoma In-Situ: Mammographic Risk Factors$324,908
R01 · FY2006 · CA · contact PI
Breast Carcinoma In-Situ: Mammographic Risk Factors$322,843
R01 · FY2005 · CA
LONG TERM OUTCOMES FOR WOMEN WITH BREAST CA IN SITU$642,897
R01 · FY2004 · CA
Breast Carcinoma In-Situ: Mammographic Risk Factors$364,367
R01 · FY2004 · CA
LONG TERM OUTCOMES FOR WOMEN WITH BREAST CA IN SITU$607,762
R01 · FY2003 · CA
LONG TERM OUTCOMES FOR WOMEN WITH BREAST CA IN SITU$580,875
R01 · FY2002 · CA
LONG TERM OUTCOMES FOR WOMEN WITH BREAST CA IN SITU$576,560
R01 · FY2001 · CA
LONG TERM OUTCOMES FOR WOMEN WITH BREAST CA IN SITU$456,618
R01 · FY2000 · CA